Although EGFR-targeting agents are currently approved for nonsmall cell lung cancer (NSCLC) on the basis of their effectiveness, the response is limited to patients with gain-of-function mutations of EGFR such as exon 19 deletion and L858R mutation [10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.